RecruitingPhase 3NCT07257198

Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone

Evaluation of an asPirin-free Strategy With ticAgrelor in patieNTs witH a Myocardial Infarction treatEd Medically alONe (PANTHEON)

Sponsor

Montreal Heart Institute

Enrollment

2,570 participants

Start Date

Mar 3, 2026

Study Type

INTERVENTIONAL

Conditions

Myocardial Infarction NSTEMI - Non-ST Segment Elevation MI STEMI (ST Elevation MI)

Summary

In patients with a myocardial infarction (MI) treated medically alone, the objective of the PANTHEON trial is to evaluate if ticagrelor monotherapy reduces bleeding events, without an increase in patient-oriented ischemic events, compared with standard dual antiplatelet therapy (DAPT) with aspirin and ticagrelor for 12 months.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Ticagrelor + aspirin and a drug called Ticagrelor + placebo for people with myocardial infarction, nstemi - non-st segment elevation mi, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.